ARTICLE | Clinical News
Matritech preclinical data
May 26, 1998 7:00 AM UTC
NMPS said that in preclinical trials its antibody detected 100 percent of precancerous, high grade or advanced cervical dysplasia, as well as 76.7 percent of precancerous low grade or early stage dysp...